Speech & Voice Disorders, University Hospital for Hearing, Medical University of Innsbruck, Innsbruck, Austria.
ICONE - Innsbruck Cognitive Neuroscience, Medical University of Innsbruck, Innsbruck, Austria.
Eur Arch Otorhinolaryngol. 2024 Dec;281(12):6669-6675. doi: 10.1007/s00405-024-08889-2. Epub 2024 Aug 23.
The goal of the study was to determine the short- and long-term outcome of health-related quality of life (HRQoL) in adults implanted with a Vibrant Soundbridge (VSB).
Twenty-one adults (8 females, 13 males; mean age at implantation: 57 ±10 years) who received a unilateral VSB for combined or conductive hearing loss, were administered two questionnaires: the Nijmegen Cochlear Implant Questionnaire (NCIQ) as a measure of hearing-specific HRQoL, and the Health Utility Index 3 (HUI 3) as a measure of generic HRQoL. The questionnaires were administered before implantation and three, six, 12 and 24 months after processor activation.
The NCIQ total score raised significantly from 62 points before implantation to 76 points at three months after processor activation (p < 0.005). Thereafter, no significant increases occurred anymore. The HUI 3 multi-attribute score (MAUS) increased from 0.59 before implantation to 0.70 at three months and at six months after processor activation and then declined slightly to 0.68 at 24 months after processor activation. Similar values were observed with the HUI 3 single-attribute score (SAUS) of Hearing. The increases of the HUI 3 scores were not statistically significant, but all pre-post-implantation differences were clinically relevant.
VSB recipients experienced a quick improvement of their HRQoL. After just three months of device use, a significant improvement of hearing-specific HRQoL and a clinically relevant improvement of generic HRQoL were seen. After three months, no essential changes of HRQoL occurred in our sample, suggesting that the achieved level of HRQoL may remain stable in the long term.
本研究旨在评估植入 Vibrant Soundbridge(VSB)的成年人短期和长期健康相关生活质量(HRQoL)的结局。
21 名成年人(8 名女性,13 名男性;植入时的平均年龄:57±10 岁)因混合性或传导性听力损失接受单侧 VSB 植入,他们接受了两份问卷评估:用于评估听力特异性 HRQoL 的奈梅亨人工耳蜗植入问卷(NCIQ)和用于评估一般 HRQoL 的健康效用指数 3(HUI 3)。在植入前和处理器激活后 3、6、12 和 24 个月进行问卷评估。
NCIQ 总分从植入前的 62 分显著提高到处理器激活后 3 个月的 76 分(p<0.005)。此后,不再有显著增加。HUI 3 多属性评分(MAUS)从植入前的 0.59 增加到处理器激活后 3 个月和 6 个月的 0.70,然后略微下降到处理器激活后 24 个月的 0.68。HUI 3 听觉单项属性评分(SAUS)也观察到类似的值。HUI 3 评分的增加没有统计学意义,但所有植入前后的差异均具有临床意义。
VSB 受者的 HRQoL 迅速改善。仅使用设备三个月后,即观察到听力特异性 HRQoL 的显著改善和一般 HRQoL 的临床相关改善。三个月后,我们的样本中 HRQoL 没有发生实质性变化,这表明获得的 HRQoL 水平可能在长期内保持稳定。